Euronext suspended all shares for Carmat on Tuesday following the death of a patient who died nine months after receiving an artificial heart transplant from the company.
According to MassDevice, the patient, a 69-year-old man, was place in intensive care after suffering circulatory failure on May 1. He died May 2.
In an interview with Le Journal du Cimanche last month, the patient stated he was feeling good and was exercising on a regular basis. He had been living with the artificial heart for eight months.
In response to the patient’s death, the Euronext stock exchange agreed to grant a suspension on the stock to allow medical teams to determine a cause of death for the patient. Carmat has concerns that the death could raise uncertainties over the efficacy of the artificial heart device.
This is the second patient to die after receiving an artificial heart transplant from Carmat. The company’s first patient, 76, passed away last year only 2 ½ months after undergoing the operation.
Despite the setback, Carmat continues to test the heart device in clinical trials.